Provigil Patent Extension Accorded To Cephalon

by Medindia Content Team on  March 31, 2006 at 6:00 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Provigil Patent Extension Accorded To Cephalon
Cephalon has been accorded a further six months of patent extension by the FDA for its pediatric sleep disorder treatment medication, Provigil.

Cephlaon had complied with the terms of an explicit written request that entailed the provision of clinical studies data after studying the effects of provigil on pediatric patients.

Cephalon has settled the 'provogil'patent infringement litigation with four generic firms, and under this settlement, each of the four defendants will have a non-exclusive royalty bearing right to market and sell a generic version of Provigil in the US, due to become effective in April 2012.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive